ATE324883T1 - Pharmazeutische zusammensetzung enthaltend lumiracoxib - Google Patents

Pharmazeutische zusammensetzung enthaltend lumiracoxib

Info

Publication number
ATE324883T1
ATE324883T1 AT02767455T AT02767455T ATE324883T1 AT E324883 T1 ATE324883 T1 AT E324883T1 AT 02767455 T AT02767455 T AT 02767455T AT 02767455 T AT02767455 T AT 02767455T AT E324883 T1 ATE324883 T1 AT E324883T1
Authority
AT
Austria
Prior art keywords
lumiracoxib
pharmaceutical composition
composition containing
pharmaceutical
containing lumiracoxib
Prior art date
Application number
AT02767455T
Other languages
English (en)
Inventor
Anees Abdulquadar Karnachi
Simon David Bateman
Original Assignee
Novartis Erfind Verwalt Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Erfind Verwalt Gmbh filed Critical Novartis Erfind Verwalt Gmbh
Application granted granted Critical
Publication of ATE324883T1 publication Critical patent/ATE324883T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02767455T 2001-08-31 2002-08-30 Pharmazeutische zusammensetzung enthaltend lumiracoxib ATE324883T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31638901P 2001-08-31 2001-08-31

Publications (1)

Publication Number Publication Date
ATE324883T1 true ATE324883T1 (de) 2006-06-15

Family

ID=23228840

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02767455T ATE324883T1 (de) 2001-08-31 2002-08-30 Pharmazeutische zusammensetzung enthaltend lumiracoxib

Country Status (29)

Country Link
US (2) US20030114527A1 (de)
EP (1) EP1425005B1 (de)
JP (1) JP4636796B2 (de)
KR (1) KR100895551B1 (de)
CN (1) CN100406008C (de)
AR (1) AR036312A1 (de)
AT (1) ATE324883T1 (de)
AU (1) AU2002331094B2 (de)
BR (1) BR0212155A (de)
CA (1) CA2456604C (de)
CO (1) CO5560554A2 (de)
CY (1) CY1106137T1 (de)
DE (1) DE60211183T2 (de)
DK (1) DK1425005T3 (de)
EC (1) ECSP044986A (de)
ES (1) ES2263813T3 (de)
HU (1) HUP0401429A2 (de)
IL (1) IL160375A0 (de)
MX (1) MXPA04001933A (de)
MY (1) MY137516A (de)
NO (1) NO20040860L (de)
NZ (1) NZ531342A (de)
PE (1) PE20030323A1 (de)
PL (1) PL367464A1 (de)
PT (1) PT1425005E (de)
RU (1) RU2329801C2 (de)
SI (1) SI1425005T1 (de)
WO (1) WO2003020261A1 (de)
ZA (1) ZA200400877B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
GB0201520D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Pharmaceutical uses
NZ534587A (en) * 2002-03-07 2007-08-31 Novartis Ag Pharmaceutical composition containing 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid to treat a cyclooxygenase-2 dependent disorder
EP2334378B1 (de) 2008-08-19 2014-04-09 XenoPort, Inc. Fumarsaeuremonomethylester-prodrugs, pharmazeutische zusammensetzungen daraus und anwendungsverfahren
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
US20140093563A1 (en) * 2011-06-13 2014-04-03 Ranbaxy Laboratories Limited Febuxostat compositions
US10952968B2 (en) 2012-05-14 2021-03-23 Shionogi & Co., Ltd. Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
JP2015527372A (ja) 2012-08-22 2015-09-17 ゼノポート,インコーポレイティド 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法
AU2013305684B2 (en) 2012-08-22 2016-11-24 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
EA018867B1 (ru) * 2012-11-01 2013-11-29 Лаборатория Тютор С.А.С.И.Ф.И.А. Способ получения фармацевтической композиции и продукт способа
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
EP3041467A1 (de) 2013-09-06 2016-07-13 XenoPort, Inc. Kristalline formen von (n,n-diethylcarbamoyl) methyl-methyl(2e)but-2-en-1,4-dioat, syntheseverfahren und verwendung
AU2015204763A1 (en) * 2014-01-10 2016-07-21 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
EP3162362A1 (de) * 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
EP4581160A1 (de) 2023-08-24 2025-07-09 10X Genomics, Inc. Verfahren, kits und zusammensetzungen für den räumlichen nachweis genetischer varianten

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0701449T3 (da) * 1993-06-08 2003-11-10 Novartis Ag Fremgangsmåde til fremstilling af en oral fast dosisform indeholdende diclofenac
JPH11512754A (ja) * 1996-05-17 1999-11-02 メルク エンド カンパニー インコーポレーテッド シクロオキシゲナーゼ―2媒介疾患の一日一回治療用組成物
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas

Also Published As

Publication number Publication date
EP1425005A1 (de) 2004-06-09
SI1425005T1 (sl) 2006-12-31
DE60211183T2 (de) 2007-02-01
NO20040860L (no) 2004-04-22
MXPA04001933A (es) 2004-06-15
CY1106137T1 (el) 2011-06-08
RU2329801C2 (ru) 2008-07-27
WO2003020261A1 (en) 2003-03-13
AR036312A1 (es) 2004-08-25
HUP0401429A2 (hu) 2004-11-29
JP2005520785A (ja) 2005-07-14
IL160375A0 (en) 2004-07-25
US20070231382A1 (en) 2007-10-04
DK1425005T3 (da) 2006-09-04
ZA200400877B (en) 2004-11-01
EP1425005B1 (de) 2006-05-03
AU2002331094B2 (en) 2006-08-31
BR0212155A (pt) 2004-07-13
ES2263813T3 (es) 2006-12-16
CA2456604C (en) 2011-02-08
CO5560554A2 (es) 2005-09-30
CA2456604A1 (en) 2003-03-13
HK1087336A1 (zh) 2006-10-13
NZ531342A (en) 2005-09-30
ECSP044986A (es) 2004-04-28
PE20030323A1 (es) 2003-05-12
KR100895551B1 (ko) 2009-04-29
RU2004109920A (ru) 2005-04-20
PL367464A1 (en) 2005-02-21
JP4636796B2 (ja) 2011-02-23
MY137516A (en) 2009-02-27
KR20040031019A (ko) 2004-04-09
DE60211183D1 (de) 2006-06-08
CN1728993A (zh) 2006-02-01
PT1425005E (pt) 2006-09-29
CN100406008C (zh) 2008-07-30
US20030114527A1 (en) 2003-06-19

Similar Documents

Publication Publication Date Title
FI20011478A0 (fi) Farmaseuttinen koostumus
DE60142197D1 (de) Pharmazeutische Zusammensetzung
DE60206889D1 (de) Pharmazeutische formulierung enthaltend bicalutamid
AT7729U3 (de) Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat
DE60213592D1 (de) Flüssige pharmazeutische zusammensetzung
NO20033556L (no) Farmasöytiske formuleringer
PL367180A1 (pl) Trwała kompozycja farmaceutyczna
NO20033384L (no) Farmasoytisk formulering
EE05020B1 (et) Glburiidi ravimkoostis
ATE320807T1 (de) Pharmazeutische zusammensetzungen enthaltend tegaserod
ATE324883T1 (de) Pharmazeutische zusammensetzung enthaltend lumiracoxib
IS7051A (is) Lyfjasamsetningar
FI20022128A7 (fi) Farmaseuttinen koostumus
ATE477814T1 (de) Stabile faktor-viii enthaltende pharmazeutische zusammensetzung
ATE350016T1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
DE60129238D1 (de) Pharmazeutische zusammensetzung
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
DE10291905D2 (de) Pharmazeutische Zusammensetzung
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
NO20033073D0 (no) Farmasöytisk sammensetning inneholdende citalopram
DE10107261B4 (de) Pharmazeutische Zusammensetzung
EP1413314A4 (de) Medizinische zusammensetzungen
FI5468U1 (fi) Farmaseuttinen koostumus
SE0100847D0 (sv) Novel pharmaceutical composition
SE0101325D0 (sv) Pharmaceutical formulation

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification

Ref document number: 1425005

Country of ref document: EP